p0
2月前
In a March 23 joint press release, Pfizer said it’s confident in the vaccine’s potential and is planning regulatory submissions for approval. Citing Pfizer’s communication, Lingelbach said a filing is planned for the second half of 2026.
https://www.fiercebiotech.com/biotech/valneva-ceo-pfizer-partnered-lyme-vaccine-why-phase-3-miss-doesnt-tell-whole-story
“What I’ve learned in my 30-plus years,” Lingelbach said, “it’s not a good idea to shape a company for being bought. It is a good idea to do your job properly, and if someone comes and buys you that creates value, […] we’re gonna deal with it. That’s our job. But we are not shaping the company or building a strategy for exit.”
p0
3月前
Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its participation in the upcoming 26th World Vaccine Congress, which will take place from March 31 to April 2, 2026 at the Walter E. convention center in Washington, D.C. Led by the Company´s Chief Executive Officer, Thomas Lingelbach, a team of Valneva´s senior executives will participate in multiple events throughout the conference.
https://valneva.com/press-release/valneva-to-participate-in-multiple-events-at-the-26th-world-vaccine-congress-in-washington-dc/
p0
5月前
George Maybach
2026-01-14 12:44
US :VALN
US
The average one-year price target for Valneva SE - Depositary Receipt (NasdaqGS:VALN) has been revised to $16.85 / share. This is an increase of 10.89% from the prior estimate of $15.20 dated December 20, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $7.60 to a high of $24.31 / share. The average price target represents an increase of 67.91% from the latest reported closing price of $10.04 / share.
There are 20 funds or institutions reporting positions in Valneva SE - Depositary Receipt.
Novo Holdings A holds 2,345K shares. In its prior filing, the firm reported owning 2,375K shares , representing a decrease of 1.28%. The firm increased its portfolio allocation in VALN by 93.96% over the last quarter.
Frazier Life Sciences Management holds 2,292K shares. In its prior filing, the firm reported owning 1,458K shares , representing an increase of 36.36%. The firm increased its portfolio allocation in VALN by 154.25% over the last quarter.
p0
10月前
Authorized in Canada - Aged 12 and Older
Valneva’s Chikungunya Vaccine IXCHIQ Now Authorized in Canada for Individuals Aged 12 and Older
August 18, 2025
And now FDA? so what ... Let's see how things might turn out in China ,)
Very contradictory, makes very little sense, and is currently not transparent at all.
It doesn't matter for sales at the moment anyway.
" Sales of IXCHIQ ®
contributed €7.5 million to the Company’s €91 million total product sales in the first half of 2025, a
significant portion of which was the result of one-time delivery of vaccine doses to combat the chikungunya outbreak in La Reunion."
p0
11月前
WHO/World Health Organization raises concern about spread of mosquito-borne Chikungunya virus
GENEVA, July 22 (Reuters) - The World Health Organization issued an urgent call for action on Tuesday to prevent a repeat of an epidemic of the mosquito-borne chikungunya virus that swept the globe two decades ago, as new outbreaks linked to the Indian Ocean region spread to Europe and other continents.
An estimated 5.6 billion people live in areas across 119 countries at risk from the virus, which can cause high fever, joint pain and long-term disability, Diana Rojas Alvarez, a medical officer at the WHO, told reporters in Geneva.
https://www.reuters.com/business/healthcare-pharmaceuticals/world-health-organization-raises-concern-about-spread-mosquito-borne-chikungunya-2025-07-22/
p0
1年前
On May 8, 2025, Valneva SE (VALN, Financial) received a revised price target from Guggenheim analyst Vamil Divan. The price target was lowered to $14.00 from the previous target of $15.00, marking a 6.67% decrease. Despite the adjustment in the price target, the analyst has maintained a 'Buy' rating on the stock.
https://www.gurufocus.com/news/2844423/valneva-valn-analyst-price-target-adjustment-by-guggenheim-valn-stock-news
p0
1年前
The results of a study conducted in the United States of 4,000 volunteers aged 18 to 65 and published in the scientific journal The Lancet were presented for approval.
The clinical trial showed that 98.9% of the participants produced neutralizing antibodies — which prevented the virus from entering cells — maintaining good levels for six months.
The chikungunya vaccine has also been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency of the European Union.
“The expectation is that, once approved and with established production capacity, the vaccine will be incorporated into the national vaccination schedule, strengthening the fight against the disease in Brazil.”
Response sent by the Ministry of Health to SciDev.Net
Chikungunya is an arbovirus, given to diseases caused by arthropod-borne viruses such as mosquitoes and ticks. It is transmitted by the bite of the mosquito Aedes aegypti, the same vector of dengue and Zika.
(translated https://blogdopedlowski.com/2025/04/24/brasil-anuncia-vacina-contra-chikungunya/)
p0
1年前
Chikungunya Outbreak in La Réunion: Valneva Responds to French Government’s Call for Vaccine Supply
https://valneva.com/press-release/valneva-responds-to-french-governments-call-for-vaccine-supply-of-ixchiq-against-chikungunya-outbreak-in-la-reunion/
March 24, 2025
Saint Herblain (France), March 24, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La Réunion with its vaccine IXCHIQ®. In agreement and with support from the local public health agency, the Agence Régionale de Santé La Réunion, Valneva will provide 40,000 doses starting early April, with an option to provide more, through distribution agreements with the Island’s wholesalers. This supply of doses, paid for by the French authorities, is in line with the recommendation of France’s national public health agency, the Haute Autorité de Santé (HAS), to prioritize for vaccination adults aged 65 and over, with co-morbidities. IXCHIQ® remains available for purchase in France (mainland and overseas).
Chikungunya cases have spiked substantially in La Réunion since early 2025, with 8,600 cases recorded and almost 3,000 new cases during the week of March 3 to 9, 2025[1]. Similar to the 2005-2006 chikungunya outbreak, there is a risk of transmission to mainland France and other French overseas territories. Local authorities of La Réunion have published a Level 4 emergency crisis management plan to contain the outbreak, while the Centers for Disease Control and Prevention (CDC) agency of the United States (U.S.) also issued a travel alert as millions of international travelers visit France’s southern resorts and La Réunion Island annually.
Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, “Chikungunya outbreaks spread rapidly, so it is crucial to vaccinate as many people as possible to help contain the virus. We have the capacity to supply more doses and will continue working closely with Agence Régionale de Santé La Réunion to manage this outbreak locally and prevent its spread to other regions through international travel.”
IXCHIQ® is the world’s first licensed chikungunya vaccine available to address this significant unmet medical need. It is approved in the United States[2], Europe[3], Canada[4] and the United Kingdom[5] for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The European Medicines Agency (EMA) recently adopted a positive opinion recommending authorization of a label extension for IXCHIQ® to individuals 12 years of age and older[6].
On March 5, 2025, the Haute Autorité de Santé recommended to prioritize for vaccination adults aged 65 and over, especially those with comorbidities, followed by adults aged 18 and over with comorbidities, and vector control workers[7].
Valneva is focused on expanding the vaccine’s label and access. In the third quarter of 2024, the Company expanded its partnership with the Coalition for Epidemic Preparedness (CEPI)[8], with support from the EU Horizon Europe program, through a $41.3 million grant to advance broader access to the vaccine in Low- and Middle-Income Countries (LMICs), post-marketing studies and research to support potential label extensions in children, adolescents and pregnant women.
Within the framework of this partnership, Valneva recently announced the signing of an exclusive license agreement with the Serum Institute of India (SII)[9], the world’s largest manufacturer of vaccines by number of doses, enabling the supply of the vaccine in Asia, with a commitment to priority supply of the chikungunya vaccine at an affordable price to public health markets in LMICs.
This new agreement complements the license agreement Valneva signed in 2021 with Instituto Butantan in Brazil for the development, manufacturing and marketing of a local chikungunya vaccine at an affordable price for distribution in Latin American countries and selected LMICs affected by the disease.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
BottomBounce
1年前
メールアドレスで登録
